Zuhair Alam

Hematology

100 High St
Buffalo, NY 14203

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

CLO26-100: Endothelial Activation and Stress Index (EASIX) Scores as Predictors of Severe Toxicity and Early Mortality After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

CLO26-100: Endothelial Activation and Stress Index (EASIX) Scores as Predictors of Severe Toxicity and Early Mortality After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis.

CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CLO26-093: Real-World First-Line Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Older Adults (≥65 Years) With Hepatocellular Carcinoma: A 1-Year Propensity-Matched Analysis.

CLO26-093: Real-World First-Line Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Older Adults (≥65 Years) With Hepatocellular Carcinoma: A 1-Year Propensity-Matched Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

CLO26-093: Real-World First-Line Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Older Adults (≥65 Years) With Hepatocellular Carcinoma: A 1-Year Propensity-Matched Analysis.

CLO26-093: Real-World First-Line Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Older Adults (≥65 Years) With Hepatocellular Carcinoma: A 1-Year Propensity-Matched Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 31, 2026

CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis.

CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

CLO26-100: Endothelial Activation and Stress Index (EASIX) Scores as Predictors of Severe Toxicity and Early Mortality After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

CLO26-100: Endothelial Activation and Stress Index (EASIX) Scores as Predictors of Severe Toxicity and Early Mortality After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Relapsed chronic lymphocytic leukemia with a cardiac mass: A case report.

Relapsed chronic lymphocytic leukemia with a cardiac mass: A case report.

Journal: Radiology case reports

Published: February 14, 2023

Economic Evaluation of a Geriatric Oncology Clinic.

Economic Evaluation of a Geriatric Oncology Clinic.

Journal: Cancers

Published: January 11, 2022

Delirium incidence, risk factors, and treatments in older adults receiving chemotherapy: A systematic review and meta-analysis.

Delirium incidence, risk factors, and treatments in older adults receiving chemotherapy: A systematic review and meta-analysis.

Journal: Journal of geriatric oncology

Published: June 17, 2020

Downstream consequences of abnormal cognitive screening in older adults seen pretreatment in a geriatric oncology clinic.

Downstream consequences of abnormal cognitive screening in older adults seen pretreatment in a geriatric oncology clinic.

Journal: Journal of geriatric oncology

Published: August 16, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026